By Colin Kellaher


Pfizer Inc. and OPKO Health Inc. on Friday said the European Medicines Agency validated for review their marketing authorization application for somatrogon, a once-weekly human-growth hormone for pediatric patients with growth-hormone deficiency.

New York drug maker Pfizer said somatrogon, if approved, would help reduce the burden of daily growth-hormone injections, adding that it expects a decision from the European Commission in 2022.

Pfizer and OPKO, a Miami healthcare-services company, signed a worldwide agreement in 2014 to develop and commercialize somatrogon for growth-hormone deficiency. The U.S. Food and Drug Administration in January accepted for review the companies' application for somatrogon.


Write to Colin Kellaher at


(END) Dow Jones Newswires

February 26, 2021 07:30 ET (12:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.